{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-047511","form_type":"8-K","ticker":"PACB","cik":"0001299130","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2024-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.765242+00:00","generated_at":"2026-06-03T22:04:28.705626+00:00","sec_items":["2.02","2.05","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PacBio reports preliminary Q1 rev $38.8M (flat YoY), slashes FY2024 guidance to $170-200M, cuts costs $50-75M","bullets":["Preliminary Q1 2024 revenue $38.8M, roughly flat vs $38.9M in prior-year period.","Revio shipments 28 systems in Q1; installed base reached 201 as of March 31, 2024.","FY2024 revenue guidance reduced to $170-200M; long-term $500M 2026 goal unlikely.","Plan to reduce annualized non-GAAP operating expense run rate by $50M-$75M by end of 2024.","Cash, cash equivalents & investments expected to be $435-450M by year-end, down from $562M at Q1 end."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-047511","json":"https://secwatch.observer/filing/0001104659-24-047511.json","markdown":"https://secwatch.observer/filing/0001104659-24-047511.md","text":"https://secwatch.observer/filing/0001104659-24-047511.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1299130/000110465924047511/0001104659-24-047511-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1299130/000110465924047511/tm2411926d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:04:28.705626+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6aae0ee207fdf9f7ed8636404fb93df5727a79ee","claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported the quarter ended March 31, 2024 results: revenue $38.8 million. Guidance lowered.","evidence_excerpt":"– PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2024. Preliminary First Quarter Results · Preliminary revenue of $38.8 million, roughly flat compared with $38.9 million in the prior-year period. · Instrument revenue of $19.0 million compared with $20.7 million in the prior-year period. · Consumables","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1299130/000110465924047511/0001104659-24-047511-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$38.8 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"7dd8571e11da4e24888c72e3bb0d2271367f3c8e","claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported 2024 results: revenue $170 million to $200 million. Guidance lowered.","evidence_excerpt":"PacBio now expects 2024 revenue to be in the range of $170 million to $200 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1299130/000110465924047511/0001104659-24-047511-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2024"},{"label":"Revenue","value":"$170 million to $200 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}